N/A
Completed N=528
Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine
Migraine Disorders
Source: ClinicalTrials.gov NCT06412965 ↗
Enrolled (actual)
528
Serious AEs
—
Results posted
Jan 2025
Primary outcomePrimary: Number of Participants Who Failed to Achieve Pain Freedom Within 2 Hours Post Dose (Physician Perspective) — 23; 167; 63; 217 Participants
Summary
This protocol describes the analysis of the Adelphi Real World (ARW) Migraine Disease Specific Programme(TM) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute treatment for migraine attacks.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Who Failed to Achieve Pain Freedom Within 2 Hours Post Dose (Physician Perspective) |
23; 167; 63; 217 | — |
| PRIMARY Number of Participants Who Reported Migraine Pain Freedom (Success) Within 2 Hours Post Dose (Participants Perspective) |
22; 67 | — |
| PRIMARY Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Physician Perspective) |
55; 103; 31; 276; 2; 33 | — |
| PRIMARY Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Physician Perspective) |
3; 26; 0; 13; 0; 17 | — |
| PRIMARY Number of Participants Classified Based on Satisfaction With Current Acute Treatment (Participants Perspective) |
17; 23; 11; 57; 0; 11 | — |
| PRIMARY Number of Participants Classified Based on Reasons for Lack of Satisfaction With Current Acute Treatment (Participants Perspective) |
0; 3; 0; 1; 1; 5 | — |
| PRIMARY Number of Participants Willing to Continue Use of Acute Treatment (Participants Perspective) |
28; 92; 1; 2 | — |
| PRIMARY Number of Participants Classified According to Responses Per Item of Migraine Treatment Optimization Questionnaire (mTOQ6) |
1; 1; 1; 7; 1; 14 | — |
| PRIMARY Number of Participants Classified Based on Timing They Took Acute Prescription Treatment |
3; 10; 21; 76; 4; 15 | — |
| PRIMARY Mean of Number of Days Per Month Participants Took Acute Prescription Treatment |
3.29; 4.04 | — |
Eligibility Criteria
Inclusion criteria
- Patients who have episodic and/or chronic migraine
- Patients age > 18
- Currently prescribed rimegepant OR triptans for the acute treatment of migraine
Exclusion criteria
- currently prescribed rimegepant for prevention of migraine or for both the acute treatment & prevention of migraine
- Rimegepant group: currently prescribed an acute treatment for migraine and other than rimegepant
- Triptan Group: currently prescribed an acute treatment for migraine other than triptans
Data sourced from ClinicalTrials.gov (NCT06412965). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.